Analgesic and Antineuropathic Drugs Acting Through Central Cholinergic Mechanisms
Open Access
- 1 May 2011
- journal article
- Published by Bentham Science Publishers Ltd. in Recent Patents on CNS Drug Discovery
- Vol. 6 (2) , 119-140
Abstract
The role of muscarinic and nicotinic cholinergic receptors in analgesia and neuropathic pain relief is relatively unknown. This review describes how such drugs induce analgesia or alleviate neuropathic pain by acting on the central cholinergic system. Several pharmacological strategies are discussed which increase synthesis and release of acetylcholine (ACh) from cholinergic neurons. The effects of their acute and chronic administration are described. The pharmacological strategies which facilitate the physiological functions of the cholinergic system without altering the normal modulation of cholinergic signals are highlighted. It is proposed that full agonists of muscarinic or nicotinic receptors should be avoided. Their activation is too intense and un-physiological because neuronal signals are distorted when these receptors are constantly activated. Good results can be achieved by using agents that are able to a) increase ACh synthesis, b) partially inhibit cholinesterase activity c) selectively block the autoreceptor or heteroreceptor feedback mechanisms. Activation of M1 subtype muscarinic receptors induces analgesia. Chronic stimulation of nicotinic (N1) receptors has neuronal protective effects. Recent experimental results indicate a relationship between repeated cholinergic stimulation and neurotrophic activation of the glial derived neurotrophic factor (GDNF) family. At least 9 patents covering novel chemicals for cholinergic system modulation and pain control are discussed.Keywords
This publication has 111 references indexed in Scilit:
- Functional Activity of the M2 and M4 Receptor Subtypes in the Spinal Cord Studied with Muscarinic Acetylcholine Receptor Knockout MiceThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Neurotrophic factors as novel therapeutics for neuropathic painNature Reviews Drug Discovery, 2003
- Peripheral Diabetic NeuropathyDrugs, 1997
- Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8Life Sciences, 1996
- Synthesis, characterization and pharmacological profile of tropicamide enantiomersLife Sciences, 1996
- S-(−)-ET 126: A potent and selectivE M1 antagonist in vitro and in vivoLife Sciences, 1996
- Inhibition of brain cell excitability by lidocaine, QX314, and tetrodotoxin: a mechanism for analgesia from infused local anesthetics?Acta Anaesthesiologica Scandinavica, 1993
- Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal ratsJournal of Neural Transmission, 1990
- Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase CBiochemical and Biophysical Research Communications, 1989
- The central action of a metabolite of tremorineLife Sciences, 1962